Follow the Adagene Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €272.2m. The latest transaction was filed on 20 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Luo Peter. The full history is free.
5
Insider Decl.
n/a
Thresholds
€80,106
3 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Adagene Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$10.74.
43Σ signal
Buys €80,106n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
22,966 shares@ US$3.646598.8% of flowAmerican Depositary Shares (ADS)SEC:0001104659-26-092176:0
Canonical exit: 2 Nov 2026 (T+90)
5 of 5 declarations
About Adagene Inc.
Adagene Inc. is a biopharmaceutical company focused on developing innovative cancer therapies. It leverages its antibody modification technology platform to enhance treatment efficacy.